Merck (NYSE: MRK) reported Q3 EPS of $2.13, $0.18 better than the analyst estimate of $1.95. Revenue for the quarter came in at $16 billion versus the consensus estimate of $15.29 billion.

GUIDANCE:

Merck sees FY2023 EPS of $3.03-$3.08, ex items, versus the consensus of $2.86. Merck sees FY2023 revenue of $59.7-60.2 billion, versus the consensus of $55.98 billion.

For earnings history and earnings-related data on Merck (MRK) click here.